NEW YORK, October 25, 2016 /PRNewswire/ --
Stock-Callers.com has initiated coverage on the following equities: Alkermes PLC (NASDAQ: ALKS), Adamis Pharmaceuticals Corp.
(NASDAQ: ADMP), BioScrip Inc. (NASDAQ: BIOS), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Register now and
get full and free access to our downloadable research reports on these stocks at: http://stock-callers.com/registration
Alkermes
Dublin, Ireland headquartered Alkermes PLC's stock finished Monday's session 1.92% higher at
$56.69. A total volume of 2.20 million shares was traded, which was above their three months
average volume of 997,050 shares. The Company's shares have advanced 14.34% in the past month and 11.14% in the previous three
months. The stock is trading 22.09% above its 50-day moving average and 33.78% above its 200-day moving average. Additionally,
shares of Alkermes, which researches, develops, and commercializes pharmaceutical products that are designed to address unmet
medical needs of patients in various therapeutic areas worldwide, have a Relative Strength Index (RSI) of 74.34.
On October 20th, 2016, Alkermes announced positive top-line results from FORWARD-5,
the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational
medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an
inadequate response to standard antidepressant therapies. The study met its pre-specified primary endpoint showing treatment with
ALKS 5461 significantly reduced symptoms of depression in patients with MDD compared to placebo. The company plans to request a
meeting with the U.S. Food and Drug Administration's (FDA) Division of Psychiatric Products to discuss the filing strategy for
this Fast Track designated medicine. Access our complete research report on ALKS for free at: http://stock-callers.com/registration/?symbol=ALKS
Adamis Pharma
On Monday, shares in San Diego, California headquartered Adamis Pharmaceuticals Corp.
recorded a trading volume of 256,363 shares. The stock ended the session 3.57% lower at $2.70. The
Company's shares are trading 9.74% below their 50-day moving average. Moreover, shares of Adamis Pharmaceuticals, which engages
in developing and commercializing products in the therapeutic areas of allergy and respiratory disease, have an RSI of 36.71. The
complimentary research report on ADMP can be downloaded at: http://stock-callers.com/registration/?symbol=ADMP
BioScrip
Denver, Colorado-based BioScrip Inc.'s stock closed the day 1.66% higher at $3.06 with a total trading volume of 576,570 shares. The Company's shares have gained 7.75% in the last month,
12.50% in the previous three months, and 74.86% on an YTD basis. The stock is trading 7.21% above its 50-day moving average and
24.89% above its 200-day moving average. Additionally, shares of BioScrip, which provides home infusion services in the US, have
an RSI of 54.46.
On October 17th, 2016, BioScrip announced that it will release its Q3 2016 financial
results on November 7th, 2016, after the close of the U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Jeffrey M.
Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call on November 8th, 2016 at 11:00 a.m. ET. Register for free on
Stock-Callers.com and get access to the latest PDF format report on BIOS at: http://stock-callers.com/registration/?symbol=BIOS
IntelliPharmaCeutics
At the close, shares in Toronto, Canada-based IntelliPharmaCeutics International Inc. ended
the day at $3.05, declining 3.17%. The stock recorded a trading volume of 579,712 shares, which was
above its three months average volume of 426,770 shares. The Company's shares have surged 44.55% in the last one month, 87.12% in
the previous three months, and 50.99% since the start of this year. The stock is trading above its 50-day and 200-day moving
averages by 43.48% and 52.81%, respectively. Furthermore, shares of IntelliPharmaCeutics International, which engages in the
research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in
Canada, have an RSI of 68.08.
On October 13th, 2016, IntelliPharmaCeutics reported that revenue related to its
license and commercialization agreement with Par Pharmaceutical, Inc. in the three months ended August
31st, 2016 was $0.6 million versus $0.8 million for
the three months ended August 31st, 2015. The Company recorded net loss for the three
months ended August 31st, 2016, of $2.1 million, or
$0.07 per common share, compared to a net loss of $1.9 million, or
$0.08 per common share, for the three months ended August
31st, 2015. Download your free research report on IPCI at: http://stock-callers.com/registration/?symbol=IPCI
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA